A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Recent clinical trials have demonstrated targeting PI3K pathway is a promising strategy for the treatment of blood cancers. To identify novel PI3K inhibitors, we performed a high throughput virtual screen and identified several novel small molecule compounds, including PIK-C98 (C98). The cell-free e...

Full description

Bibliographic Details
Main Authors: Zhu, Jingyu, Wang, Man, Yu, Yang, Qi, Huixin, Han, Kunkun, Tang, Juan, Zhang, Zubin, Zeng, Yuanying, Cao, Biyin, Qiao, Chunhua, Zhang, Hongjian, Hou, Tingjun, Mao, Xinliang
Format: Online
Language:English
Published: Impact Journals LLC 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381587/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381587/

Similar Items